Cure8 news brief
The tool aims to reduce algorithm- and cohort-specific bias when deriving gene signatures, which could help produce more reproducible biomarkers relevant to Crohn’s disease and IBD research.
Researchers, data scientists, and clinicians focused on IBD biomarker discovery and transcriptomic methods.
The research team built TENTACLES to combine many classifiers and clustering methods so that gene signatures are selected by consensus across algorithms and validated across independent RNA-seq cohorts.
The authors applied the tool to Crohn’s disease using 689 intestinal biopsy profiles from four public bulk RNA-seq datasets and report ensemble-based discovery and external validation steps.
The pipeline includes normalization, batch correction, multi-model tuning, aggregation of variable-importance rankings, and systematic testing of compact gene subsets for cross-cohort separability.
This is a methods-focused, research-stage study applied to public bulk RNA-seq datasets; it does not equate to a validated clinical biomarker and will need additional prospective and functional validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
A noninvasive saliva test combined with machine learning could make it easier and faster to classify pediatric IBD subtypes and to monitor patients, potentially reducing reliance on invasive tests and speeding treatment...
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
